Challenges Facing Chinese Biotech Deals

Can Chinese biotech deals continue amid increasingly stringent U.S. and Chinese restrictions?

By CLP staff

Chinese pharmaceuticals and life sciences companies have garnered increasing interest from overseas companies due to their ability to develop drugs and conduct clinical trials at a faster pace and significantly lower cost than in the West.

Exclusive Content

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

Access to 3000+ essential documents, including key PRC laws translated into English
Newsletters with business-critical and sector-specific updates
Premium mobile access with timely analysis on China’s fast-changing market

Already a Subscriber? Log In Here

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)